Is yet to decide about the partnership or acquisition route
.jpg)
ITC, TCS and HDFC Bank emerged as the biggest gainers during the period.
FDA had cancelled Ranbaxy's approvals to launch generic Nexium, Valcyte
The Hinduja Group, Mukesh Ambani, Murugappa, and the Adani groups were the other gainers in the Modi regime, while Naveen Jindal and Sun Pharma groups saw the most erosion in their m-cap in the last five years, reports Krishna Kant.
Competition watchdog says 'high market concentration' in some segments a worry.
In 2008, the 13 companies on the list accounted for 34 per cent of the overall m-cap.
The deal had separately come under scanner of the market regulator Sebi for alleged insider trading violations and the present 'no-objection' from the exchanges.
A global policy would reward firms which strive for higher quality.
As on July 31, the valuation of his shareholding in the company stood at Rs 9,830 crore.
Sun Pharma's Dilip Shanghvi is India's richest person.
Ranbaxy was asked to sell all products containing Leuprorelin which are marketed and supplied under brand name Eligard.
The combined market valuation of top six Sensex companies surged by Rs 26,346 crore last week, with Reliance Industries and HDFC contributing the most to the gains.
Sun Pharma's offer was tempting because Ranbaxy was too busy fighting fires in the US to concentrate on operations.
4 Ranbaxy facilities in India have been barred from exporting to US.
The Gurgaon-headquartered drug maker, set to be acquired by another leading domestic company, Sun Pharmaceutical Industries, reported a consolidated net loss of Rs 186 crore for the quarter ended June.
Industry is gathering scientific data to approach the regulator, DCGI, for a review of the suspension order.
The FDA has stepped up its efforts to ensure drug safety in recent months.
Hero MotoCorp's promoter Pawan Munjal emerged as the highest paid director.
In 2014, Sun Pharma agreed to buy Ranbaxy -- which was then controlled by Daiichi.
The BSE Mid-cap index gained 1.1% while the Small-cap index surged 1.3%, outperforming the benchmark indices
Sun Pharma to retain these in most markets; US could be the exception, where the Ranbaxy name has taken a hit.
On January 31, the US Federal Trade Commission cleared the merger.
Launches cloud-based version of solution to target mid-size clients in life sciences.
Ranbaxy Laboratories on Wednesday reported widening of its consolidated net loss to Rs 1,029.72 crore (Rs 10.29 billion) for the third quarter ended December 31, 2014
Amneal Pharmaceuticals is set to pip Sun Pharma as the fifth largest generics maker in the US, reports Sohini Das.
Analysts say those taking exposure through stocks could look at firms focused on domestic business
A source said the competition watchdog would by next month suggest 'structural remedies' that included selling key drug segments as conditions for clearing the country's largest pharmaceutical industry merger.
It goes without saying that the best performers are in the private sector, says TN Ninan.
The Nifty50 slipped 33 points to close the session at 8,509 after hitting an intra-day high of 8,587.
The turmoil on the Street and a continued fall of the rupee may affect growth stocks, pushing equity investors back to the relative safety of defensive counters, or forcing them to flee markets, or both.
Currently, only three have completed more than six months of operation in the space - Fino Payments Bank, Airtel Payments Bank and Paytm
On October 2, a legislature committee wrote letters to the 14 companies, initiating an investigation and seeking details about recent price increases in several generic products available in the American market.
The US Food and Drug Administration (FDA) says it does not follow an India agenda.
The year saw 30 QIP deals raising over $5 billion and 35 IPOs.
Top losers are Sun Pharma, Bajaj Auto, L&T, ITC, Hero Moto.
Some Indian generic drugmakers are, however, uncertain about the pace of approvals in the near future.
In August, RBI allowed 11 business houses to start a payments bank.
In 2013, Daiichi had launched the arbitration proceedings in Singapore.
Slapped with Rs 242-crore fine by US authorities for rule violations at Toansa unit, say sources; 2nd such hefty rap in the recent past from US regulators for bending rules.
US will remain a growth driver, with launches & existing portfolios set to result in 15% growth for FY15.
